Significance of Recent Financing for Epigenic Therapeutics
Epigenic Therapeutics, a pioneering company focused on innovative gene modulation therapies, has successfully completed a significant financing round. This funding, amounting to $60 million, was led by Lapam Capital and included continued support from existing investors as well as interest from new investors. This investment plays a crucial role in propelling the clinical development of promising treatments and technologies aimed at addressing chronic health conditions.
Optimizing Development of Epigenetic Medicines
The primary objective of this funding is to further the clinical development of EPI-003, a promising candidate aimed at providing a functional cure for chronic hepatitis B. Alongside this, funding will support EPI-001 for the treatment of hypercholesterolemia. These advancements showcase Epigenic’s commitment to developing effective therapies that target prevalent health challenges.
Innovative Technology Platforms at Epigenic
One of the standout features of Epigenic is its proprietary EPIREG™ technology platform. This cutting-edge platform enables specific and sustained silencing of target genes through precise mechanisms such as DNA methylation and histone modification. Unlike traditional gene-editing tools, which pose various safety risks, EPIREG™ represents a revolutionary approach to therapeutics, significantly enhancing patient safety in chronic disease treatment.
Expanding Delivery Mechanisms
In addition to EPIREG™, Epigenic has developed the EpiTax™ platform, an advanced delivery system designed to precisely deliver therapeutic agents to the liver and other organs. This innovation broadens EPIREG™'s potential applications, enriching Epigenic's overall technological framework and positioning it competitively within the biotechnology landscape.
Empowering Epigenetic Medicine Through AI
The AIAID™ platform, another novel system developed by Epigenic, streamlines the design and modulation processes of epigenetic treatments. This platform integrates a self-developed model that supports core epigenetic data analysis and decision-making. Utilizing a virtual lab concept, AIAID™ facilitates tasks essential for research advancement, including target selection, sgRNA design, and the evaluation of potential therapies.
Leadership and Vision
Dr. Bob Zhang, the CEO and Co-founder of Epigenic Therapeutics, expressed gratitude toward the investors for their trust and support. Since its establishment, the company has achieved significant milestones in advancing epigenetic technologies and remains focused on delivering safe and effective therapies to patients as quickly as possible. Notably, industry leaders recognize Epigenic's potential for fostering innovation in epigenetic therapies.
Community Support from Investors
Mr. Zhihua Yu, Chairman of Lapam Capital, acknowledged the unique advantages that Epigenic brings to the field of drug development. The technological foundation established by EPIREG™ and EpiTax™ positions the firm for future breakthroughs in clinical trials, further allowing them to solidify their presence in the innovative healthcare space.
About Epigenic Therapeutics
As a forefront biotechnology company established in 2021, Epigenic Therapeutics is committed to developing next-generation gene modulation therapies. The company focuses on leveraging epigenetic regulation to treat a variety of diseases, and develops several promising product candidates aimed at metabolic, cardiovascular, and autoimmune diseases.
About Lapam Capital
Lapam Capital is a leading venture capital firm that specializes in the biomedical sector. The firm has managed multiple funds, focusing on innovative pharmaceuticals and medical devices. Their strategy emphasizes supporting early to mid-stage companies, thus fostering growth within the biotech sector.
Frequently Asked Questions
What is the purpose of the recent financing for Epigenic Therapeutics?
The financing aims to support the clinical development of EPI-003 and EPI-001, crucial treatments targeting hepatitis B and hypercholesterolemia.
What technologies are being developed at Epigenic Therapeutics?
Epigenic is advancing technologies like EPIREG™ for gene modulation and EpiTax™ for targeted drug delivery, enhancing safety and efficacy in treatments.
Who are the key investors in Epigenic Therapeutics?
The recent funding round was led by Lapam Capital, with participation from existing investors such as Qiming Venture Partners and OrbiMed, along with new investors.
What challenges does Epigenic aim to address?
Epigenic focuses on prevalent chronic diseases, intending to develop safe and effective therapies while mitigating safety concerns associated with traditional gene editing.
How can I learn more about Epigenic Therapeutics?
For further information, individuals can explore Epigenic's website to understand their mission, technologies, and ongoing projects.
